Entera Reports Third-Quarter 2026 Results and Business Updates
Entera said preparations advanced for its EB613 Phase 3 osteoporosis study, with first site activation expected in late 2026. The company also expanded clinical and commercial leadership and highlighted EB613 at an ASBMR plenary poster presentation.
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and DirectorsEB613 Enhanced Anabolic Effect Highlighted at ASBMR Plenary Poster PresentationIND-Enab…